NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment of cancers of the liver, announced today that Dr. James F. Pingpank will present at The Fourth International Symposium on Regional Cancer Therapies, to be held February 21-23, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) Dr. Pingpank, Adjunct Principal Investigator of Delcath's Phase III Trial treating ocular and cutaneous melanoma metastatic to the liver, and Principal Investigator of the trial at the University of Pittsburgh Medical Center, will deliver two oral presentations titled: Impact of High-dose Melphalan (MEL) Administered via Hepatic Arterial Infusion for Patients with Unresectable Hepatic Metastases from Neuroendocrine Tumors (MNET) and Multi-institutional Clinical Trials in Regional Therapy for Liver Metastases Commenting on the relevance of these topics, Richard L. Taney, President and CEO of Delcath Systems, stated, "As we move toward completion of our pivotal Phase III Trial, Dr. Pingpank's updates provide an invaluable communication to the other leaders in the field of regional cancer treatment. Dr. Pingpank and Dr. Marybeth Hughes, Principal Investigator of the Phase III Study at the National Cancer Institute, continue to show their dedication to the trial." The Phase III Study The Phase III clinical study is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. This clinical study is testing Delcath's PHP(TM) System for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath PHP System(TM) is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while preventing entry of the drugs to the rest of the patient's circulation. This isolation limits toxicities that result from systemic chemotherapy treatments. Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath PHP System(TM) or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to "cross over" and receive treatment with the Delcath System. The Fourth International Symposium on Regional Cancer Therapies The Fourth International Symposium on Regional Cancer Therapies will take place February 21-23, 2009 in Marco Island, Florida. The Symposium is sponsored by the David C. Koch Regional Cancer Therapy Center, the University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences and UPMC Cancer Centers. The Koch Regional Cancer Therapy Center is committed to promoting research; development and application of regional cancer therapies; and exchanging information and promoting education among professionals regarding regional cancer therapies. More information on this conference can be found at http://www.regionaltherapies.com/. About Delcath Systems, Inc. Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at http://www.delcath.com/. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made. http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO http://photoarchive.ap.org/ DATASOURCE: Delcath Systems, Inc. CONTACT: Richard Taney of Delcath Systems, Inc., +1-212-489-2100, ; or Public Relations, Robin Wagge of Rubenstein Associates, Inc., +1-212-843-8006, , for Delcath Systems, Inc. Web Site: http://www.delcath.com/ http://www.regionaltherapies.com/

Copyright